Item 1. Financial Statements
96K characters. Original on sec.gov ·
Item 1. Financial Statements
| Financial Statements |
Condensed Consolidated Statements of Earnings
(Unaudited)
| Three Months Ended September 30, | |||||||||||
| (in millions, except per common share amounts) | 2026 | 2025 | |||||||||
| Revenue | $ | 67,513 | $ | 64,009 | |||||||
| Cost of products sold | 64,917 | 61,690 | |||||||||
| Gross margin | 2,596 | 2,319 | |||||||||
| Operating expenses: | |||||||||||
| Distribution, selling, general, and administrative expenses | 1,595 | 1,461 | |||||||||
| Restructuring and employee severance | 23 | 20 | |||||||||
| Amortization and other acquisition-related costs | 182 | 104 | |||||||||
| Acquisition-related cash and share-based compensation costs | 94 | 64 | |||||||||
| Impairments and (gain)/loss on disposal of assets, net | (4) | 2 | |||||||||
| Litigation (recoveries)/charges, net | (47) | — | |||||||||
| Operating earnings | 753 | 668 | |||||||||
| Other (income)/expense, net | (6) | (10) | |||||||||
| Interest expense, net | 73 | 80 | |||||||||
| Impairment of equity interest in Outcomes | (2) | — | |||||||||
| Earnings before income taxes | 688 | 598 | |||||||||
| Provision for income taxes | 132 | 144 | |||||||||
| Net earnings | 556 | 454 | |||||||||
| Less: Net earnings attributable to noncontrolling interests | (2) | (4) | |||||||||
| Net earnings attributable to Cardinal Health, Inc. | $ | 554 | $ | 450 | |||||||
| Earnings per common share attributable to Cardinal Health, Inc.: | |||||||||||
| Basic | $ | 2.39 | $ | 1.89 | |||||||
| Diluted | $ | 2.38 | $ | 1.88 | |||||||
| Weighted-average number of common shares outstanding: | |||||||||||
| Basic | 232 | 238 | |||||||||
| Diluted | 233 | 239 | |||||||||
| Cash dividends declared per common share | $ | 0.5158 | $ | 0.5107 |
See notes to condensed consolidated financial statements.
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 19 |
| Financial Statements |
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Net earnings | $ | 556 | $ | 454 | |||||||
| Other comprehensive income/(loss): | |||||||||||
| Foreign currency translation adjustments and other | 4 | (4) | |||||||||
| Net unrealized gain/(loss) on derivative instruments, net of tax | 2 | — | |||||||||
| Total other comprehensive income/(loss), net of tax | 6 | (4) | |||||||||
| Total comprehensive income | 562 | 450 | |||||||||
| Less: comprehensive income attributable to noncontrolling interests | (2) | (4) | |||||||||
| Total comprehensive income attributable to Cardinal Health, Inc. | $ | 560 | $ | 446 |
See notes to condensed consolidated financial statements.
| 20 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Financial Statements |
Condensed Consolidated Balance Sheets
| (in millions) | September 30, 2026 | June 30, 2026 | |||||||||
| Assets | (Unaudited) | ||||||||||
| Current assets: | |||||||||||
| Cash and equivalents | $ | 5,264 | $ | 4,856 | |||||||
| Trade receivables, net | 14,542 | 13,815 | |||||||||
| Inventories, net | 18,395 | 17,297 | |||||||||
| Prepaid expenses and other | 2,781 | 2,764 | |||||||||
| Assets held for sale | 8 | 21 | |||||||||
| Total current assets | 40,990 | 38,753 | |||||||||
| Property and equipment, net | 2,999 | 3,031 | |||||||||
| Goodwill and other intangibles, net | 13,689 | 13,631 | |||||||||
| Other assets | 1,866 | 1,884 | |||||||||
| Total assets | $ | 59,544 | $ | 57,299 | |||||||
| Liabilities and Shareholders’ Deficit | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 40,937 | $ | 38,283 | |||||||
| Current portion of long-term obligations and other short-term borrowings | 1,886 | 1,882 | |||||||||
| Other accrued liabilities | 3,503 | 3,739 | |||||||||
| Total current liabilities | 46,326 | 43,904 | |||||||||
| Long-term obligations, less current portion | 6,929 | 7,004 | |||||||||
| Deferred income taxes and other liabilities | 9,155 | 9,115 | |||||||||
| Shareholders’ deficit: | |||||||||||
| Preferred shares, without par value: | |||||||||||
| Authorized—500 thousand shares, Issued—none | — | — | |||||||||
| Common shares, without par value: | |||||||||||
| Authorized—755 million shares, Issued—271 million shares at September 30, 2026 and June 30, 2026 | 2,773 | 2,887 | |||||||||
| Retained earnings | 2,438 | 2,009 | |||||||||
| Common shares in treasury, at cost: 39 million shares and 38 million shares at September 30, 2026 and June 30, 2026, respectively | (8,077) | (7,614) | |||||||||
| Accumulated other comprehensive loss | (159) | (165) | |||||||||
| Total Cardinal Health, Inc. shareholders' deficit | (3,025) | (2,883) | |||||||||
| Noncontrolling interests | 159 | 159 | |||||||||
| Total shareholders’ deficit | (2,866) | (2,724) | |||||||||
| Total liabilities and shareholders’ deficit | $ | 59,544 | $ | 57,299 |
See notes to condensed consolidated financial statements.
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 21 |
| Financial Statements |
Condensed Consolidated Statements of Shareholders' Deficit
(Unaudited)
| Common Shares | Treasury Shares | Accumulated Other Comprehensive Loss | Noncontrolling Interests | Total Shareholders’ Deficit | |||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Shares Issued | Amount | Retained Earnings | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | 271 | $ | 2,887 | $ | 2,009 | (38) | $ | (7,614) | $ | (165) | $ | 159 | $ | (2,724) | |||||||||||||||||||||||||||||||||
| Net earnings | 554 | 2 | 556 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | 6 | 6 | |||||||||||||||||||||||||||||||||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | (115) | 1 | 42 | (73) | ||||||||||||||||||||||||||||||||||||||||||
| Share repurchase program activity | — | (2) | (505) | (505) | |||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | (125) | (125) | |||||||||||||||||||||||||||||||||||||||||||||
| Payments to noncontrolling interests | (3) | (3) | |||||||||||||||||||||||||||||||||||||||||||||
| Other | 1 | 1 | 2 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | 271 | $ | 2,773 | $ | 2,438 | (39) | $ | (8,077) | $ | (159) | $ | 159 | $ | (2,866) |
| Three Months Ended September 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | 271 | $ | 2,956 | $ | 783 | (32) | $ | (6,365) | $ | (155) | $ | 147 | $ | (2,634) | |||||||||||||||||||||||||||||||||
| Net earnings | 450 | 4 | 454 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss, net of tax | (4) | (4) | |||||||||||||||||||||||||||||||||||||||||||||
| Acquisitions | (1) | (1) | |||||||||||||||||||||||||||||||||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | (135) | 1 | 86 | (49) | ||||||||||||||||||||||||||||||||||||||||||
| Share repurchase program activity | (75) | (2) | (303) | (378) | |||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | (117) | (117) | |||||||||||||||||||||||||||||||||||||||||||||
| Payments of noncontrolling interests | (3) | (3) | |||||||||||||||||||||||||||||||||||||||||||||
| Other | 1 | 1 | |||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | 271 | $ | 2,746 | $ | 1,116 | (33) | $ | (6,582) | $ | (159) | $ | 148 | $ | (2,731) |
See notes to condensed consolidated financial statements.
| 22 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Financial Statements |
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Cash flows from operating activities: | |||||||||||
| Net earnings | $ | 556 | $ | 454 | |||||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 247 | 233 | |||||||||
| Impairments and (gain)/loss on sale of other investments, net | 16 | 5 | |||||||||
| Impairment and (gain)/loss on sale of equity interest in Outcomes, net | (2) | — | |||||||||
| Impairments and (gain)/loss on disposal of assets, net | (4) | 2 | |||||||||
| Share-based compensation | 109 | 93 | |||||||||
| Provision for bad debts | 14 | 13 | |||||||||
| Change in operating assets and liabilities, net of effects from acquisitions and divestitures: | |||||||||||
| Increase in trade receivables | (734) | (539) | |||||||||
| Increase in inventories | (1,171) | (736) | |||||||||
| Increase in accounts payable | 2,653 | 2,147 | |||||||||
| Repurchases of liability-classified Specialty Alliance Units | (4) | (16) | |||||||||
| Other accrued liabilities and operating items, net | (282) | (683) | |||||||||
| Net cash provided by operating activities | 1,398 | 973 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Acquisition of subsidiaries, net of cash acquired | (149) | (41) | |||||||||
| Additions to property and equipment | (157) | (108) | |||||||||
| Proceeds from investments | 34 | 9 | |||||||||
| Proceeds from disposal of property and equipment | 15 | — | |||||||||
| Other investing items, net | 6 | (2) | |||||||||
| Net cash used in investing activities | (251) | (142) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Proceeds from long-term obligations, net of issuance costs | — | 989 | |||||||||
| Reduction of long-term obligations | (11) | (512) | |||||||||
| Payments to noncontrolling interests, net | (3) | (3) | |||||||||
| Net tax withholding from share-based compensation | (102) | (80) | |||||||||
| Dividends on common shares | (126) | (129) | |||||||||
| Purchase of treasury shares | (500) | (375) | |||||||||
| Net cash used in financing activities | (742) | (110) | |||||||||
| Effect of exchange rates changes on cash and equivalents | 3 | (2) | |||||||||
| Net increase in cash and equivalents | 408 | 719 | |||||||||
| Cash and equivalents at beginning of period | 4,856 | 3,874 | |||||||||
| Cash and equivalents at end of period | $ | 5,264 | $ | 4,593 |
See notes to condensed consolidated financial statements.
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 23 |
| Notes to Financial Statements |
Notes to Condensed Consolidated Financial Statements
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2027 and 2026 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2027 and June 30, 2026, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2027 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2027. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in
our Annual Report on Form 10-K for the fiscal year ended June 30, 2026 (the "2026 Form 10-K").
Variable Interest Entities
We evaluate our ownership, contractual, and other interests in entities to determine if they are a variable interest entity (“VIE”), if we have a variable interest in those entities, and the nature and extent of those interests. These evaluations may involve management judgment and the use of estimates and assumptions based on available historical information, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements.
Consolidated Variable Interest Entities
We consolidate a VIE when we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits that could be significant to the VIE and, as a result, are considered the primary beneficiary of the VIE.
We have concluded that The Specialty Alliance management services organization ("MSO") and Navista are the primary beneficiaries of certain physician practices and therefore the practices are consolidated as VIEs. The Specialty Alliance and Navista VIEs do not have a material impact on our consolidated statements of earnings or consolidated statements of cash flows. Total assets and liabilities included in the consolidated balance sheets for The Specialty Alliance and Navista VIEs were $1.3 billion and $1.1 billion, respectively, as of September 30, 2026.
Noncontrolling Interests
Noncontrolling interests represent the portion of net earnings, comprehensive income, and net assets that is not attributable to Cardinal Health, Inc. Noncontrolling interests as of September 30, 2026 primarily represents third-party equity interests in Navista.
Recently Issued Financial Accounting Standards And Disclosure Rules Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from the 2026 Form 10-K.
Disaggregation of Income Statement Expenses
In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregated disclosures of certain categories of expenses which are included in any relevant income statement expense caption on an annual and interim basis. Additionally, the guidance requires the disclosure of total selling expenses and, in annual reporting periods, an entity's definition of selling expenses. This guidance
| 24 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Notes to Financial Statements |
will be effective for us in our fiscal 2028 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Accounting for Internal-Use Software
In September 2025, the FASB issued ASU 2025-06 Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The guidance amends the accounting and the disclosure of software costs, including website development costs. This guidance will be effective in our fiscal 2029 Form 10-K and may be applied using a prospective, retrospective, or modified transition approach. Early adoption is permitted. We are currently evaluating the impact of adoption of this guidance on our accounting and disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the three months ended September 30, 2026.
2. Acquisitions
Solaris Health
On November 3, 2025, we, through The Specialty Alliance, completed the acquisition of Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments. In connection with the closing of this transaction, we issued common units in the Specialty Alliance to certain physicians and management which are estimated to have a grant date fair value of approximately $500 million, a portion of which will be recognized as post-combination expense within acquisition-related cash and share-based compensation costs.
Transaction and integration costs associated with the Solaris acquisition were $3 million during the three months ended September 30, 2026.
Fair Value of Assets Acquired and Liabilities Assumed
The allocation of the purchase price for the acquisition of Solaris Health is not yet finalized and is subject to adjustment as we complete the valuation analysis of this acquisition. The purchase price is also subject to adjustment based on working capital requirements as set forth in the acquisition agreement.
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Solaris Health:
| (in millions) | Solaris Health | ||||
| Identifiable intangible assets: | |||||
| Trade names (1) | $ | 233 | |||
| Non-competition agreements (2) | 39 | ||||
| Total identifiable intangible assets acquired | 272 | ||||
| Identifiable net assets/(liabilities): | |||||
| Cash and equivalents | 55 | ||||
| Trade receivables, net | 208 | ||||
| Inventories | 23 | ||||
| Prepaid expenses and other | 73 | ||||
| Property and equipment, net | 62 | ||||
| Other assets | 193 | ||||
| Accounts payable | (106) | ||||
| Current portion of long-term obligations and other short-term borrowings | — | ||||
| Other accrued liabilities | (175) | ||||
| Long-term obligations, less current portion | — | ||||
| Deferred income taxes and other liabilities | (194) | ||||
| Total identifiable net assets/(liabilities) acquired | 411 | ||||
| Noncontrolling interest | — | ||||
| Goodwill | 1,726 | ||||
| Total net assets acquired | $ | 2,137 |
(1) The useful life of trade names is 10 years.
(2) The useful life of non-competition agreements is 5 years.
The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement. The discount rate used to arrive at the present value of the identifiable intangible assets for Solaris Health was 7 percent, and reflects the internal rate of return and uncertainty in the cash flow projections, which is reflective of market participant assumptions.
The fair value of the Solaris Health trade name intangible asset was determined utilizing the relief from royalty method, an income-based approach. Under this method, a royalty rate based on observed market royalties is applied to projected revenue supporting the trade name and discounted to present value using an appropriate discount rate.
The fair value of the non-compete intangibles acquired from Solaris Health were determined by applying the differential cash flow method which compares the present value of cash flows with and without the non-compete agreements in place.
The vested Specialty Alliance Units, issued in relation to the Solaris Health acquisition, were recognized at their acquisition date fair value of $210 million and are included in deferred income taxes and other liabilities in the condensed balance sheet. The valuation of The Specialty Alliance Units utilizes significant unobservable inputs and thus represents a recurring Level 3 fair value measurement. The fair value of The Specialty Alliance Units in relation to the Solaris Health acquisition was determined using a discount rate of 7.5 percent and an estimated weighted average service period of five years.
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 25 |
| Notes to Financial Statements |
3. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Employee-related costs | $ | 11 | $ | 15 | |||||||
| Facility exit and other costs | 12 | 5 | |||||||||
| Total restructuring and employee severance | $ | 23 | $ | 20 |
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional project management, and costs associated with vacant facilities.
During the three months ended September 30, 2026, restructuring and employee severance costs were primarily related to the implementation of cost-savings and other strategic initiatives. During the three months ended September 30, 2025, restructuring and employee severance costs were primarily related to the implementation of cost-savings initiatives.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
| (in millions) | Employee- Related Costs | Facility Exit and Other Costs | Total | ||||||||||||||
| Balance at June 30, 2026 | $ | 55 | $ | — | $ | 55 | |||||||||||
| Additions | 8 | — | 8 | ||||||||||||||
| Payments and other adjustments | (18) | — | (18) | ||||||||||||||
| Balance at September 30, 2026 | $ | 45 | $ | — | $ | 45 |
4. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the carrying amount of goodwill by segment and in total:
| (in millions) | Pharmaceutical and Specialty Solutions | Global Medical Products and Distribution | Other (1) | Total | |||||||||||||||||||
| Balance at June 30, 2026 | $ | 9,695 | $ | — | $ | 1,747 | $ | 11,442 | |||||||||||||||
| Goodwill acquired, net of purchase price adjustments | 34 | — | 67 | 101 | |||||||||||||||||||
| Balance at September 30, 2026 | $ | 9,729 | $ | — | $ | 1,814 | $ | 11,543 |
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
During the three months ended September 30, 2026, we did not identify any indicators of impairment within our reporting units.
Goodwill increased in the three months ended September 30, 2026 due to recent acquisitions as well as purchase accounting adjustments in the Pharma segment and at-Home Solutions.
Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount.
As described in Note 2, the purchase price and assumed fair value of acquisitions is allocated to specific assets, resulting in the carrying amount approximating the fair value as of the acquisition date. Accordingly, we expect minimal excess of estimated fair value over carrying value for recent acquisitions. We will continue to evaluate acquisitions and the related reporting units for indicators of impairment.
Other Intangible Assets
The following tables summarize other intangible assets by class at:
| September 30, 2026 | |||||||||||||||||||||||
| (in millions) | Gross Intangible | Accumulated Amortization | Net Intangible | Weighted- Average Remaining Amortization Period (Years) | |||||||||||||||||||
| Indefinite-life intangibles: | |||||||||||||||||||||||
| Trademarks and patents | $ | 24 | $ | — | $ | 24 | N/A | ||||||||||||||||
| Total indefinite-life intangibles | 24 | — | 24 | N/A | |||||||||||||||||||
| Definite-life intangibles: | |||||||||||||||||||||||
| Customer intangibles | 4,134 | 2,851 | 1,283 | 9 | |||||||||||||||||||
| Trademarks, trade names and patents | 1,128 | 574 | 554 | 8 | |||||||||||||||||||
| Developed technology and other | 928 | 689 | 239 | 5 | |||||||||||||||||||
| Non-Competition Agreements | 82 | 36 | 46 | 4 | |||||||||||||||||||
| Total definite-life intangibles | 6,272 | 4,150 | 2,122 | 8 | |||||||||||||||||||
| Total other intangible assets | $ | 6,296 | $ | 4,150 | $ | 2,146 | N/A |
| 26 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Notes to Financial Statements |
| June 30, 2026 | |||||||||||||||||
| (in millions) | Gross Intangible | Accumulated Amortization | Net Intangible | ||||||||||||||
| Indefinite-life intangibles: | |||||||||||||||||
| Trademarks and patents | $ | 24 | $ | — | $ | 24 | |||||||||||
| Total indefinite-life intangibles | 24 | — | 24 | ||||||||||||||
| Definite-life intangibles: | |||||||||||||||||
| Customer intangibles | 4,097 | 2,814 | 1,283 | ||||||||||||||
| Trademarks, trade names and patents | 1,139 | 558 | 581 | ||||||||||||||
| Developed technology and other | 1,030 | 779 | 251 | ||||||||||||||
| Non-Competition Agreements | 83 | 33 | 50 | ||||||||||||||
| Total definite-life intangibles | 6,349 | 4,184 | 2,165 | ||||||||||||||
| Total other intangible assets | $ | 6,373 | $ | 4,184 | $ | 2,189 |
Total amortization of intangible assets was $100 million and $87 million for the three months ended September 30, 2026 and 2025, respectively.
The following table summarizes the estimated annual amortization for intangible assets for the remainder of fiscal 2027 through fiscal 2031:
| (in millions) | Estimated Amortization Expense | ||||
| 2027 | $ | 295 | |||
| 2028 | 358 | ||||
| 2029 | 333 | ||||
| 2030 | 311 | ||||
| 2031 | 258 |
5. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $8.8 billion and $8.9 billion at September 30, 2026 and June 30, 2026, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $40.9 billion and $38.3 billion at September 30, 2026 and June 30, 2026, respectively.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2026 include a $4.0 billion commercial paper program, backed by a $4.0 billion revolving credit facility that expires in August 2031. At September 30, 2026, we had no amounts outstanding under our commercial paper program or our revolving credit facility.
On August 7, 2026, we entered into a consolidated $4.0 billion 5-year revolving credit facility, in conjunction with the terminations of the $2.0 billion revolving credit facility, the $1.0 billion 364-Day revolving credit facility, and the $1.0 billion committed receivables sales facility.
On September 15, 2026, we also increased our commercial paper program to $4.0 billion. This program is backstopped by our revolving credit facility.
Between October 29 and November 2, 2026, we entered into $1 billion of uncommitted revolving credit facilities.
Our revolving credit facility requires us to maintain a consolidated net leverage ratio of no greater than 4.00-to-1.00. As of September 30, 2026, we were in compliance with this financial covenant.
6. Commitments, Contingent Liabilities, and Litigation
Commitments
Generic Sourcing Venture with CVS Health
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Legal Proceedings
We become involved from time to time in disputes, litigation, and regulatory matters.
From time to time, we determine that products we distribute, source, manufacture, or market do not meet our specifications, regulatory requirements, or published standards. While we investigate and take appropriate action when we or a regulatory agency identify a potential quality or regulatory issue, there is no assurance that the issue will be resolved to the satisfaction of the regulator. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits, and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption, or anti-bribery laws. When we become aware of such possible compliance matters, we investigate and take appropriate corrective action.
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 27 |
| Notes to Financial Statements |
In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier, or other industry participants. Internal investigations, subpoenas, or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in corrective actions or sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from certain disputes that occur in the ordinary course of business are included within segment profit.
Opioid Lawsuits and Investigations
As of September 30, 2026, we have $3.9 billion accrued for the opioid-related matters described below, of which $197 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the three months ended September 30, 2026 and fiscal 2026, we made payments totaling $385 million and $417 million, respectively, which included our annual payments under the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities.
While we continue to incur certain costs associated with these matters, during the three months ended September 30, 2026 and fiscal 2026, there were no material expenses recognized for these matters.
States & Political Subdivisions
We have resolved, without admitting liability, the opioid-related claims of all 50 states, the District of Columbia, and 5 U.S. territories. The National Opioid Settlement Agreement ("the NOSA") also resulted in the resolution of the opioid-related claims of over 99 percent of political subdivisions (together, the "Settling Governmental Entities").
To date, we have paid the Settling Governmental Entities approximately $2.6 billion and we expect to pay the Settling Governmental Entities additional amounts up to $3.7 billion through 2038.
In July 2022, a judgment in favor of the Distributors was entered in a bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. In October 2025, the United States Court of Appeals for the Fourth Circuit vacated the district court's judgment and remanded the case for further proceedings. In May 2026, the parties submitted additional briefing to the district court and a ruling is pending. We intend to continue to vigorously defend ourselves in this matter.
Private Plaintiffs
The NOSA does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals alleging personal injury. To date, there are approximately 56 lawsuits brought by private plaintiffs pending. Of these, approximately 9 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in all of these matters.
Following resolution discussions with certain private plaintiffs during December 2024, Distributors finalized agreements with classes of third-party payors and acute care hospitals. Our portion of these settlements totaled $213 million. The settlement with the class of third-party payors was approved by the court in January 2025 and was finalized in August 2025. The settlement with the class of acute care hospitals was approved by the court in March 2025 and became final in April 2025.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above, including two matters currently pending in Ohio state court. Unfavorable outcomes in these matters would negatively impact our financial results and may result in a change in loss reserves related to opioid litigation recorded by our captive insurance company, which would negatively impact cash flow.
During fiscal 2026, we received immaterial insurance recoveries related to opioid matters, which were recorded in the Pharma segment. We have not recorded a receivable for any additional recoveries related to these insurance litigation matters as of September 30, 2026.
| 28 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Notes to Financial Statements |
Department of Justice Civil Investigative Demand
In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation.
Tax Contingencies
Net Operating Loss Carryback
In June 2026, we received a Notice of Proposed Adjustment ("NOPA") from the Internal Revenue Service ("IRS") as part of our 2015-2020 audit cycle. The NOPA relates to our captive insurance company and the treatment of certain net operating loss carrybacks under the Coronavirus Aid, Relief, and Economic Security Act. The IRS is challenging the tax deductibility of self-insurance pre-tax losses and related carryback claims to fiscal 2015-2018, which could result in approximately $400 million in additional tax expense (plus interest) and approximately $1.4 billion in additional tax liability (plus interest). We routinely assess the likelihood of adverse audit outcomes to ensure adequate tax reserves, and we believe our reserves are sufficient for all tax matters. The ultimate resolution of this matter may impact our financial results and cash flow.
Patient Recovery Restructuring
In February 2026, we received a NOPA from the IRS, as part of our ongoing audits of fiscal years 2015-2020, related to a restructuring in connection with our July 2017 acquisition of the Patient Recovery business. The IRS is asserting that the transaction should be recharacterized in a manner that could create additional federal income tax liability of approximately $160 million, plus interest. We routinely assess the likelihood of adverse outcomes resulting from audits and examinations to determine the adequacy of our tax reserves and we believe we have adequate reserves for all tax matters; however, the ultimate outcome of disputes of this nature is uncertain and the resolution of this matter could impact our financial results and cash flow.
Antitrust Litigation Proceeds
We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $47 million during the three months ended September 30, 2026.
7. Income Taxes
Fluctuations in our provision for income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Effective Tax Rate
During the three months ended September 30, 2026 and 2025, the effective tax rate was 19.2 percent and 24.1 percent, respectively.
Unrecognized Tax Benefits
We had $900 million and $907 million of unrecognized tax benefits at September 30, 2026 and June 30, 2026, respectively. The September 30, 2026 and June 30, 2026 balances include $883 million and $881 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At September 30, 2026 and June 30, 2026, we had $78 million and $75 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.
During fiscal 2026, we received two NOPAs from the IRS in connection with their audit of our fiscal years 2015-2020. See Note 6 for additional information regarding these matters.
8. Fair Value Measurements
Assets and Liabilities Measured on a Recurring Basis
The following tables present the fair values for assets and liabilities measured on a recurring basis at:
| September 30, 2026 | |||||||||||||||||||||||
| (in millions) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Cash equivalents | $ | 2,704 | $ | — | $ | — | $ | 2,704 | |||||||||||||||
| Other investments (1) | 112 | — | — | 112 | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
| Forward contracts (2) | — | (107) | — | (107) | |||||||||||||||||||
| Share-based awards (3) | — | — | (1,353) | (1,353) | |||||||||||||||||||
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 29 |
| Notes to Financial Statements |
| June 30, 2026 | |||||||||||||||||||||||
| (in millions) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Cash equivalents | $ | 2,299 | $ | — | $ | — | $ | 2,299 | |||||||||||||||
| Other investments (1) | 118 | — | — | 118 | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
| Forward contracts (2) | — | (32) | — | (32) | |||||||||||||||||||
| Share-based awards (3) | — | — | (1,277) | (1,277) |
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2) The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
(3) The share-based awards are liability-classified awards, as defined under ASC 718, resulting from acquisitions by The Specialty Alliance. These are presented in deferred income taxes and other liabilities within the consolidated balance sheets. The fair value of The Specialty Alliance Units is determined using the discounted cash flow method which utilizes significant unobservable inputs, including the discount rate of 8.0%. Significant changes to assumptions used in the valuation may have a material impact on the fair value of the Specialty Alliance Units. See Note 13 for additional information.
Changes in Level 3 Recurring Fair Value Measurements
The following table reconciles the changes in fair value for the Specialty Alliance Units classified within Level 3 of the fair value hierarchy:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Balance at beginning of period | $ | 1,277 | $ | 843 | |||||||
| Acquisitions | — | 20 | |||||||||
| Vesting (1) | 46 | 53 | |||||||||
| Fair value adjustment (1) | 34 | 10 | |||||||||
| Repurchases | (4) | (16) | |||||||||
| Balance at end of period | $ | 1,353 | $ | 910 |
(1)For the three months ended September 30, 2026 and 2025, there was $80 million and $63 million of expense, respectively, for the Specialty Alliance Units. Of the total expense recognized during the three months ended September 30, 2026 and 2025, $78 million and $61 million is included in acquisition-related cash and share-based compensation costs, respectively, and $2 million is included in SG&A expenses, for both periods, in the consolidated statements of earnings.
9. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks
managed through the use of derivative instruments include interest rate risk and currency exchange risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency revenue and expenses.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2026 and 2025, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the three months ended September 30, 2026 and 2025, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $300 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt
| 30 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Notes to Financial Statements |
and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate and foreign currency fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains and losses recognized in other comprehensive income were immaterial for both the three months ended September 30, 2026 and 2025. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2026 and 2025, respectively. Gains currently included within accumulated other comprehensive income associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In September 2026, we terminated the ¥18 billion ($120 million) cross-currency swaps entered into in September 2025 and received settlement in cash of $6 million, recorded in other investing items, net in our condensed consolidated statements of cash flows.
In September 2025, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2027.
In September 2025, we terminated the ¥18 billion ($120 million) cross-currency swaps entered into in September 2023 and received settlement in cash of $3 million, recorded in other investing items, net in our condensed consolidated statements of cash flows.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were immaterial for the three months ended
September 30, 2026 and 2025, respectively. Losses recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were immaterial during both the three months ended September 30, 2026 and 2025.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions, and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net in the consolidated statement of earnings. We recorded immaterial losses during both the three months ended September 30, 2026 and 2025. The principal currencies managed through foreign currency contracts are the Canadian dollar, Japanese yen, Chinese renminbi, Brazilian real, and Singapore dollar.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, net, accounts payable, and other accrued liabilities at September 30, 2026 and June 30, 2026 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
| (in millions) | September 30, 2026 | June 30, 2026 | |||||||||
| Estimated fair value | $ | 8,402 | $ | 8,783 | |||||||
| Carrying amount | 8,815 | 8,886 |
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
10. Shareholders' Deficit
We repurchased $500 million and $375 million of our common shares, in the aggregate, through share repurchase programs during the three months ended September 30, 2026 and 2025, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 31 |
| Notes to Financial Statements |
The following table presents the accelerated share repurchase programs executed during the three months ended September 30, 2026 and 2025:
| Quarter Entered | Date Concluded | Aggregate Purchase Price (in millions) | Initial Shares (in millions) | Reference Price | Final Shares (in millions) | Weighted Average Price per Common Share | ||||||||||||||
| Q1 FY27 | 9/18/2026 | $500 | 1.7 | $234.16 | 0.5 | $231.63 | ||||||||||||||
| Q1 FY26 | 10/31/2025 | $375 | 2.0 | $148.12 | 0.4 | $151.88 |
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
| (in millions) | Foreign Currency Translation Adjustments | Unrealized Gain/(Loss) on Derivatives, net of tax | Accumulated Other Comprehensive Loss | ||||||||||||||
| Balance at June 30, 2026 | $ | (140) | $ | (25) | $ | (165) | |||||||||||
| Other comprehensive income, before reclassifications | 4 | 4 | 8 | ||||||||||||||
| Amounts reclassified to earnings | — | (2) | (2) | ||||||||||||||
| Total other comprehensive income attributable to Cardinal Health, Inc., net of tax benefit of $7 million | 4 | 2 | 6 | ||||||||||||||
| Balance at September 30, 2026 | $ | (136) | $ | (23) | $ | (159) |
| (in millions) | Foreign Currency Translation Adjustments | Unrealized Gain/(Loss) on Derivatives, net of tax | Accumulated Other Comprehensive Loss | ||||||||||||||
| Balance at June 30, 2025 | $ | (141) | $ | (14) | $ | (155) | |||||||||||
| Other comprehensive (loss)/income, before reclassifications | (4) | 2 | (2) | ||||||||||||||
| Amounts reclassified to earnings | — | (2) | (2) | ||||||||||||||
| Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $1 million | (4) | — | (4) | ||||||||||||||
| Balance at September 30, 2025 | $ | (145) | $ | (14) | $ | (159) |
11. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc. ("EPS"):
| Three Months Ended September 30, | |||||||||||
| (in millions, except per share amounts) | 2026 | 2025 | |||||||||
| Net earnings | $ | 556 | $ | 454 | |||||||
| Net earnings attributable to noncontrolling interest | (2) | (4) | |||||||||
| Net earnings attributable to Cardinal Health, Inc. | $ | 554 | $ | 450 | |||||||
| Weighted-average common shares–basic | 232 | 238 | |||||||||
| Effect of dilutive securities: | |||||||||||
| Employee stock options, restricted share units, and performance share units | 1 | 1 | |||||||||
| Weighted-average common shares–diluted | 233 | 239 | |||||||||
| Basic earnings per common share attributable to Cardinal Health, Inc.: | $ | 2.39 | $ | 1.89 | |||||||
| Diluted earnings per common share attributable to Cardinal Health, Inc.: | $ | 2.38 | $ | 1.88 |
For the three months ended September 30, 2026 and 2025, an immaterial amount of restricted share units and performance share units were excluded from the computation of diluted EPS, as they were anti-dilutive.
12. Segment Information
We operate under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") and Global Medical Products and Distribution ("GMPD"). All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; repackages generic pharmaceuticals and over-the-counter healthcare products; and includes our managed services organization platforms for physician offices.
Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and
| 32 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Notes to Financial Statements |
other markets. This segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.
The remaining three non-reportable operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States, and provide supply chain services and solutions to our customers.
Revenue
The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Pharmaceutical and Specialty Solutions | $ | 62,582 | $ | 59,205 | |||||||
| Global Medical Products and Distribution | 3,190 | 3,184 | |||||||||
| Nuclear and Precision Health Solutions | 505 | 436 | |||||||||
| at-Home Solutions | 1,146 | 1,115 | |||||||||
| OptiFreight® Logistics | 113 | 90 | |||||||||
| Other | 1,764 | 1,641 | |||||||||
| Total segment revenue | 67,536 | 64,030 | |||||||||
| Corporate (1) | (23) | (21) | |||||||||
| Total revenue | $ | 67,513 | $ | 64,009 |
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| United States | $ | 67,113 | $ | 63,611 | |||||||
| International | 423 | 419 | |||||||||
| Total segment revenue | 67,536 | 64,030 | |||||||||
| Corporate (1) | (23) | (21) | |||||||||
| Total revenue | $ | 67,513 | $ | 64,009 |
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
The Company’s Chief Executive Officer, the chief operating decision maker ("CODM"), evaluates segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate technology and shared functions expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the operating segments based on headcount, level of benefit provided, and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
-
last-in first-out, or ("LIFO"), inventory charges/(credits);
-
state opioid assessment related to prior fiscal years;
-
restructuring and employee severance;
-
amortization and other acquisition-related costs;
-
acquisition-related cash and share-based compensation costs;
-
impairments and (gain)/loss on disposal of assets, net;
-
litigation (recoveries)/charges, net;
-
other (income)/expense, net;
-
interest expense, net;
-
impairment of equity interest in Outcomes; or
-
provision for income taxes
In addition, certain investment spending and certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $15 million and $16 million for the three months ended September 30, 2026 and 2025, respectively.
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 33 |
| Notes to Financial Statements |
The following table presents segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
| Three Months Ended September 30, 2026 | |||||||||||||||||||||||
| (in millions) | Pharma | GMPD | Other | Total | |||||||||||||||||||
| Segment revenue | $ | 62,582 | $ | 3,190 | $ | 1,764 | $ | 67,536 | |||||||||||||||
| Cost of products sold | 61,001 | 2,636 | 1,303 | 64,940 | |||||||||||||||||||
| SG&A | 798 | 521 | 268 | 1,587 | |||||||||||||||||||
| Total segment expenses | 61,799 | 3,157 | 1,571 | 66,527 | |||||||||||||||||||
| Segment profit | $ | 783 | $ | 33 | $ | 193 | $ | 1,009 | |||||||||||||||
| Corporate (1) | (321) | ||||||||||||||||||||||
| Consolidated earnings before income taxes | $ | 688 |
| Three Months Ended September 30, 2025 | |||||||||||||||||||||||
| (in millions) | Pharma | GMPD | Other | Total | |||||||||||||||||||
| Segment revenue | $ | 59,205 | $ | 3,184 | $ | 1,641 | $ | 64,030 | |||||||||||||||
| Cost of products sold | 57,857 | 2,633 | 1,221 | 61,711 | |||||||||||||||||||
| SG&A | 681 | 505 | 254 | 1,440 | |||||||||||||||||||
| Total segment expenses | 58,538 | 3,138 | 1,475 | 63,151 | |||||||||||||||||||
| Segment profit | $ | 667 | $ | 46 | $ | 166 | $ | 879 | |||||||||||||||
| Corporate (1) | (281) | ||||||||||||||||||||||
| Consolidated earnings before income taxes | $ | 598 |
(1) Corporate consists of the income and expense items not allocated to the segments and the elimination of inter-segment revenue.
Segment Assets
The following table presents total assets for two reportable segments and the remaining operating segments, included in Other, and Corporate:
| (in millions) | September 30, 2026 | June 30, 2026 | |||||||||
| Pharmaceutical and Specialty Solutions | $ | 42,472 | $ | 40,777 | |||||||
| Global Medical Products and Distribution | 6,819 | 6,651 | |||||||||
| Other | 4,269 | 4,098 | |||||||||
| Corporate | 5,984 | 5,773 | |||||||||
| Total assets | $ | 59,544 | $ | 57,299 |
The following tables present depreciation and amortization and additions to property and equipment for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Pharmaceutical and Specialty Solutions | $ | 60 | $ | 61 | |||||||
| Global Medical Products and Distribution | 56 | 55 | |||||||||
| Other | 28 | 29 | |||||||||
| Corporate | 103 | 88 | |||||||||
| Total depreciation and amortization | $ | 247 | $ | 233 |
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Pharmaceutical and Specialty Solutions | $ | 45 | $ | 32 | |||||||
| Global Medical Products and Distribution | 16 | 19 | |||||||||
| Other | 20 | 15 | |||||||||
| Corporate | 76 | 42 | |||||||||
| Total additions to property and equipment | $ | 157 | $ | 108 |
The following table presents property and equipment, net by geographic area:
| (in millions) | September 30, 2026 | June 30, 2026 | |||||||||
| United States | $ | 2,579 | $ | 2,607 | |||||||
| International | 420 | 424 | |||||||||
| Total property and equipment, net | $ | 2,999 | $ | 3,031 |
13. Share-Based Compensation
We maintain Cardinal Health, Inc. corporate stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors, and employees. As of September 30, 2026, we have 16 million shares authorized for issuance under the Plans. Upon vesting, these units convert to common shares without restrictions or future service requirements.
| 34 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
| Notes to Financial Statements |
The following table provides total share-based compensation expense by type of award:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Restricted share unit expense | $ | 18 | $ | 18 | |||||||
| Performance share unit expense | 11 | 12 | |||||||||
| Total share-based compensation | $ | 29 | $ | 30 |
The total tax benefit related to share-based compensation was $5 million and $4 million for the three months ended September 30, 2026 and 2025, respectively. Share-based compensation expense is included in selling, general, and administrative expenses in the condensed consolidated statements of earnings. Our condensed consolidated statements of cash flows present our share-based compensation expense as a reconciling adjustment between net income and net cash provided by operating activities for all periods presented.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
| (in millions, except per share amounts) | Restricted Share Units | Weighted-Average Grant Date Fair Value per Share | |||||||||
| Nonvested at June 30, 2026 | 1.1 | $ | 85.89 | ||||||||
| Granted | 0.3 | 235.17 | |||||||||
| Vested | (0.5) | 111.21 | |||||||||
| Canceled and forfeited | — | — | |||||||||
| Nonvested at September 30, 2026 | 0.9 | $ | 154.32 |
The total fair value of units vested during the three months ended September 30, 2026 and 2025 were $52 million and $53 million, respectively.
At September 30, 2026, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $120 million, which is expected to be recognized over a weighted-average period of two years.
Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved and our total shareholder return relative to the S&P 500 Health Care Index, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
| (in millions, except per share amounts) | Performance Share Units | Weighted-Average Grant Date Fair Value per Share | |||||||||
| Nonvested at June 30, 2026 | 1.2 | $ | 117.07 | ||||||||
| Granted | 0.2 | 245.49 | |||||||||
| Vested | (0.5) | 94.66 | |||||||||
| Canceled and forfeited | — | — | |||||||||
| Nonvested at September 30, 2026 | 0.9 | $ | 153.35 |
The total fair value of units vested during the three months ended September 30, 2026 and 2025 were $110 million and $108 million, respectively.
At September 30, 2026, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $63 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.
Specialty Alliance Share-Based Compensation
The Specialty Alliance, a majority-owned subsidiary of Cardinal Health, maintains standalone share-based compensation plans. Share-based compensation expense associated with these awards of $80 million and $63 million was recognized during the three months ended September 30, 2026 and 2025, respectively. Of the expense recognized for the three months ended September 30, 2026 and 2025, $78 million and $61 million is included in acquisition-related cash and share-based compensation costs, respectively, and $2 million is included in SG&A expenses, for both periods, in the condensed consolidated statements of earnings, respectively. We recognize activity within SG&A expenses for awards that are granted in relation to regular course of business and are not acquisition-related. The liability and associated future expenses may vary based on the changes in the estimated fair value.
The following table summarizes the fair market value of The Specialty Alliance Units as of September 30, 2026:
| (in millions, except per share amounts) | Specialty Alliance Share Units | Fair Value per Share | |||||||||
| Nonvested at June 30, 2026 | 266 | $ | 1.53 | ||||||||
| Granted | 2 | 1.57 | |||||||||
| Vested | (31) | 1.57 | |||||||||
| Canceled and forfeited | — | 1.57 | |||||||||
| Nonvested at September 30, 2026 | 237 | $ | 1.57 | ||||||||
| Vested at September 30, 2026 | 864 | $ | 1.57 |
The total fair value of The Specialty Alliance Units vested during the three months ended September 30, 2026 and 2025 was $46 million and $53 million, respectively. During the three months ended September 30, 2026 and 2025, we recognized adjustments to the fair value of the liability, resulting in expense of $34 million and $10 million, respectively, related to the vested Specialty
| Cardinal Health | Q1 Fiscal 2027 Form 10-Q | 35 |
| Notes to Financial Statements |
Alliance Units, which is recognized in acquisition-related cash and share-based compensation costs.
At September 30, 2026, the total pre-tax compensation cost related to nonvested Specialty Alliance Units not yet recognized was $372 million, which is expected to be recognized over a weighted-average period of approximately four years.
| 36 | Cardinal Health | Q1 Fiscal 2027 Form 10-Q |
Previous: Item 5. Other Information · Next: Item 6. Exhibits